Pharmaceutical research organizations are increasingly structuring Phase II and Phase III clinical trials around decentralized, sensor-driven monitoring protocols.
Data Fidelity
Continuous biometric data collection offers researchers higher longitudinal fidelity than periodic in-clinic evaluations, improving early detection of adverse events and efficacy signals.
Operational Efficiency
Decentralized models reduce trial drop-out rates by over 30%, cutting overall drug development timelines and associated capital expenditures significantly.